Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels

92Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: Persistent activation of STING pathway is the basis for several autoimmune diseases. STING is activated by cGAMP, which is produced by cGAS in the presence of DNA. Results/methodology: HPLC-based medium throughput screening for inhibitors of cGAS identified suramin as a potent inhibitor. Unlike other reported cGAS inhibitors, which bind to the ATP/GTP binding site, suramin displaced the bound DNA from cGAS. Addition of suramin to THP1 cells reduced the levels of IFN-β mRNA and protein. Suramin did not inhibit lipopolysaccharide-or Pam3CSK4-induced IL-6 mRNA expression. Conclusion: Suramin inhibits STING pathway via the inhibition of cGAS enzymatic activity. Suramin or analogs thereof that displace DNA from cGAS could be used as anti-inflammatory drugs.

Cite

CITATION STYLE

APA

Wang, M., Sooreshjani, M. A., Mikek, C., Opoku-Temeng, C., & Sintim, H. O. (2018). Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels. Future Medicinal Chemistry, 10(11), 1301–1317. https://doi.org/10.4155/fmc-2017-0322

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free